New drug targets tumors from inside: early trial begins
NCT ID NCT07454642
First seen Mar 07, 2026 · Last updated Jun 09, 2026 · Updated 11 times
Summary
This early-phase trial tests a new drug called AVA6103 in about 174 adults with advanced solid tumors (like pancreatic, lung, or breast cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, aiming to kill cancer cells while limiting side effects. The main goals are to check safety and find the best dose, with initial signs of tumor shrinkage also being measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.